HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

Core Viewpoint - HilleVax, Inc. reported its financial results for the first quarter of 2025, highlighting a significant reduction in net loss and ongoing development of norovirus vaccine candidates [1][3]. Financial Performance - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $159.5 million, down from $171.4 million as of December 31, 2024 [2][8]. - Research and development expenses for Q1 2025 were $2.0 million, a decrease from $26.0 million in Q1 2024, primarily due to lower clinical development costs [2][7]. - General and administrative expenses for Q1 2025 were $5.6 million, down from $8.5 million in Q1 2024, mainly due to reduced personnel-related costs [3][7]. - Other income for Q1 2025 was $1.5 million, compared to $3.0 million in Q1 2024, driven by lower accretion of marketable securities [3]. - The net loss for Q1 2025 was $6.1 million, significantly reduced from $46.8 million in Q1 2024 [3][7]. Company Overview - HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, specifically targeting norovirus with its candidates HIL-214 and HIL-216 [4]. - Norovirus is responsible for over 700 million cases of acute gastroenteritis globally and results in approximately 200,000 deaths annually, leading to over $4 billion in direct health system costs and $60 billion in societal costs [4].